BUY MBP DACLATASVIR DIHYDROCHLORIDE DACLITOF-60 28TAB BEST PRICE ONLINE IN NIGERIA LAGOS ABUJA KANO AND PORTHARCOURT AT MYBIGPHARMACY.COM

Description

Dear friend, this medication requires a prescription or medical license before it can be delivered to you. kindly ensure that you provide us with a reliable contact information at checkout, mybigpharmacy team will be in touch with you to obtain required document before your order is confirmed thank you for trusting mybig pharmacy with your health. Daclatasvir dihydrochloride is an antiviral medicine used in the treatment of chronic hepatitis C virus infection. It belongs to a class of medicines known as direct-acting antivirals and works by targeting a specific protein the hepatitis C virus needs to multiply and survive. Daclatasvir dihydrochloride specifically inhibits the NS5A protein, which plays a key role in viral replication and assembly. By blocking this protein, daclatasvir prevents the virus from multiplying and helps clear the infection from the body.

Daclatasvir dihydrochloride is not used alone. It is always given in combination with other antiviral medicines such as sofosbuvir, and sometimes ribavirin, depending on the hepatitis C genotype, liver condition, and treatment history of the patient. When used correctly in combination therapy, daclatasvir dihydrochloride can achieve cure rates above 90 percent, meaning the virus becomes undetectable and does not return after treatment is completed.

Daclatasvir dihydrochloride is taken orally, usually once daily, with or without food. It should be taken at the same time each day to maintain stable drug levels in the body. Consistency is essential because missed doses can reduce effectiveness and increase the risk of viral resistance. The usual treatment duration is 12 weeks, although some patients may require 24 weeks depending on liver damage, previous treatment failure, or co-infection.

Once treatment begins, the viral load usually drops quickly, often within the first few weeks. Many patients report improved energy levels and overall wellbeing as the virus is suppressed. However, it is important to complete the full course even if symptoms improve early, as stopping treatment too soon can allow the virus to return.

Daclatasvir dihydrochloride is generally well tolerated. Common side effects include fatigue, headache, nausea, and mild gastrointestinal discomfort. These side effects are usually mild and temporary. When used with ribavirin, side effects such as anaemia, shortness of breath, and weakness may occur and require closer monitoring.

This medication can interact with several other drugs. Strong enzyme inducers such as rifampicin, carbamazepine, phenytoin, phenobarbital, and St John?s wort can significantly reduce daclatasvir levels and must not be used together. Some antifungal medicines, antibiotics, and HIV medications may also require dose adjustments. It is essential that all medicines, supplements, and herbal products are disclosed to a healthcare provider before starting treatment.

Daclatasvir dihydrochloride should be used with caution in patients with advanced liver disease and must be carefully monitored through blood tests. Liver function tests are typically done before treatment and periodically during therapy to ensure safety and effectiveness.

In patients co-infected with hepatitis B, reactivation of hepatitis B can occur during or after treatment for hepatitis C. For this reason, screening for hepatitis B is required before starting daclatasvir, and appropriate monitoring or treatment may be necessary.

Daclatasvir dihydrochloride should not be used during pregnancy unless absolutely necessary. When combined with ribavirin, pregnancy must be strictly avoided due to the risk of severe birth defects. Effective contraception is required during treatment and for several months after completion if ribavirin is used.

Daclatasvir dihydrochloride does not prevent transmission of hepatitis C during treatment. Safe practices should continue until cure is confirmed. Cure is defined as sustained virologic response, meaning no detectable hepatitis C virus in the blood 12 weeks after completing therapy.

When taken correctly and under medical supervision, daclatasvir dihydrochloride is a highly effective and well-tolerated treatment for hepatitis C. It has transformed hepatitis C from a chronic, progressive disease into a curable condition for most patients, significantly reducing the risk of liver failure, cirrhosis, and liver cancer.